Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- PAFSC’s 2nd Committee on New Drugs to Discuss Approval for Pfizer Japan’s ALK Inhibitor Xalkori
February 16, 2012
- Osaka Prefecture Asking Korosho to Provide Pharmaceutical Strategy Consultation Services in Kansai Region
February 16, 2012
- Over 30 Companies Target Nu-lotan Generic Listing in June, 60% Pricing Rule to Apply
February 15, 2012
- Prof. Matsumoto of OPMI Stresses Need to Enhance Competitiveness of Pharmaceutical Industry
February 14, 2012
- MHLW Postpones Ban of Dispensing Points to October
February 14, 2012
- PAFSC’s First Committee on Drugs to Review Astellas’ Hyperphosphatemia Treatment on February 24
February 14, 2012
- Healthcare Providers, Bill Payers in Face-Off Over Additional Premiums for Generic Name Prescriptions
February 13, 2012
- CSIMC’S Medical Fee Reform Plan for FY2012 to Promote Faster Patient Discharge, Functional Specialization
February 13, 2012
- FY2012 Medical Fee Revision to Include New Measures to Promote Generic Drug Use
February 13, 2012
- Guidance Fee for Psychiatric Patients to Be Reduced from 55 to 44 Points When Prescribing 3 or More Drugs
February 10, 2012
- Delivery Price Settlement Rate Just 79.1% at End of December: MHLW
February 9, 2012
- Selection Process for Clinical Research Core Hospitals to Begin in Early March
February 9, 2012
- US FDA Warns against Risk of CDAD in Patients Taking PPIs
February 9, 2012
- Drug Discovery Support Organization Needed to Prevent “Decay” of Drug Industry: Mr Hachiyama
February 8, 2012
- Prime Minister Noda Asks Korosho to Study Simultaneous Revisions of Medical, Nursing Fees Every 3 Years
February 7, 2012
- Japan’s Cancer Registry System Lags Behind Other Developed Countries: Mr Umemura of DPJ
February 7, 2012
- Growing Concerns that Premium for New Drug Development May Violate Antimonopoly Act
February 6, 2012
- National, Rosai Hospitals to Enhance Relationship Aiming at Joint Purchasing in July
February 3, 2012
- MHLW to Strengthen Counterfeit Drug Control Creating Public-Private Council
February 3, 2012
- PAFSC's 2nd Committee on Drugs Recommends Approval for Kyowa Kirin's ATL Treatment
February 2, 2012
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…